Literature DB >> 17368956

Consideration of acamprosate for treatment of amyotrophic lateral sclerosis.

Richard E Kast1, Eric Lewin Altschuler.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal disease of degeneration of motor neurons. There is no known cure or life extending treatment. Much recent work has suggested that a possible cause of ALS is constitutive opening of the calcium pore in glutamate sensitive AMPA channels secondary to a failure of RNA editing that would change a crucial glutamate in the channel to arginine. Here, we point out that the small molecule pharmaceutical acamprosate, usually used as a drug to maintain alcohol abstinence, may block this calcium pore--as do the related molecules endogenous polyamines such as putrescine, cadaverine, spermidine and spermine--and thus might have use in ALS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368956     DOI: 10.1016/j.mehy.2007.01.072

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

Review 1.  AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future.

Authors:  M Scott Bowers; Billy T Chen; Antonello Bonci
Journal:  Neuron       Date:  2010-07-15       Impact factor: 17.173

2.  Acamprosate modulates experimental autoimmune encephalomyelitis.

Authors:  Z Sternberg; A Cesario; K Rittenhouse-Olson; R A Sobel; Yi-Kan Leung; O Pankewycz; B Zhu; T Whitcomb; D S Sternberg; F E Munschauer
Journal:  Inflammopharmacology       Date:  2011-11-17       Impact factor: 4.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.